https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=ORIC_Pharmaceuticals%2C_Inc.ORIC Pharmaceuticals, Inc. - Revizia istoricului2026-04-06T14:12:51ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=ORIC_Pharmaceuticals,_Inc.&diff=434383&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei ORIC Pharmaceuticals, Inc. listata cu simbolul US.ORIC ==Descriere companie== ORIC Pharmaceuticals Inc. (http://oricpharma.com/) is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancer...2024-09-18T18:19:15Z<p>Pagină nouă: Pagina dedicata companiei ORIC Pharmaceuticals, Inc. listata cu simbolul US.ORIC ==Descriere companie== ORIC Pharmaceuticals Inc. (http://oricpharma.com/) is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancer...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei ORIC Pharmaceuticals, Inc. listata cu simbolul US.ORIC<br />
<br />
==Descriere companie==<br />
ORIC Pharmaceuticals Inc. (http://oricpharma.com/) is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its product candidates include ORIC-101, ORIC-533, ORIC-944 and ORIC-114. The Company’s ORIC-101 is a potent and selective small-molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. The Company’s second product candidate, ORIC-533, is an orally bioavailable, small-molecule inhibitor of CD73, a key node in the adenosine pathway in resistance to chemotherapy-and immunotherapy-based treatment regimens. Its ORIC-944, is being developed for prostate cancer and breast cancer.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.ORIC" /><br />
<br />
==Ultimele stiri despre ORIC Pharmaceuticals, Inc. (US.ORIC)==<br />
<dynamicpagelist><br />
category=US.ORIC<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.ORIC]][[Categorie:Stiri despre companii]]</div>Admin